Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention

Circulation

Volumn 105, Issue 6, 2002, Pages 691-696

  Chan, Albert W ^a   Bhatt, Deepak L ^a   Chew, Derek P ^a   Quinn, Martin J ^a   Moliterno, David J ^a   Topol, Eric J ^a   Ellis, Stephen G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angioplasty; Coronary disease; Mortality; Statins; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOGENIC SHOCK; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE PREDISPOSITION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; THROMBOCYTE ADHESION; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREMEDICATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STENTS; SURVIVAL ANALYSIS;

EID: 0037065895     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0602.103586     Document Type: Article

References (36)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group
4. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study. A randomized controlled trial
5. Early statin treatment following acute myocardial infarction and 1-year survival
6. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
7. Cholesterol sulfate: A new adhesive molecule for platelets
8. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
9. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
10. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
11. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
12. Effect of statins on C-reactive protein in patients with coronary artery disease
13. Statins and C-reactive protein
14. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) investigators
15. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) investigators
16. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
17. Estimating causal effects from large data sets using propensity scores
18. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
19. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty: The PREDICT Trial Investigators. Prevention of Restenosis by Elisor After Transluminal Coronary Angioplasty
20. Lack of effect of lovastatin on restenosis after coronary angioplasty: Lovastatin Restenosis Trial Study Group
21. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
22. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
23. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
24. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies
25. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
26. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
27. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
28. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
29. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina
30. Plasma levels of C-reactive protein after coronary stent implantation
31. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation
32. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention
33. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group. Fragmin during instability in coronary artery disease
34. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease
35. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
36. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study